BioMarin Pharmaceutical — Feb 19, 2025 release

• In 2025, full year Total Revenues guidance represents 10% Y/Y growth at the mid-point, expected to be driven by VOXZOGO’s continued global expansion and solid demand across Enzyme Therapies. The company is on track to deliver its previously targeted Total Revenues of approximately $4 billion in 2027. Non-GAAP Operating Margin is expected to grow 14% (3.9 percentage points) Y/Y at the mid-point of guidance and Non-GAAP Diluted EPS is expected to increase 22% Y/Y at the mid-point of guidance, as a result of continued strong commercial execution and focus on operational efficiencies across the business. • The company generated operating cash flows totaling $573 million in full year 2024, an increase of 260% compared to full year 2023. Total cash and investments at the end of the fourth quarter were approximately $1.7 billion, and with anticipated increasing profitability, BioMarin is positioned to generate increasing operating cash flow into the future, targeting more than $1.25 billion operating cash flows per year starting in 2027. 3 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 % Change 2024 2023 % Change Total Revenues $747 $646 16% $2,854 $2,419 18% Net Product Revenues by Product: VOXZOGO $208 $146 42% $735 $470 56% Enzyme Therapies: VIMIZIM $191 $176 9% $740 $701 6% NAGLAZYME 110 98 12% 480 420 14% PALYNZIQ 100 88 14% 355 304 17% BRINEURA 48 44 9% 169 162 4% ALDURAZYME 39 43 (9)% 184 131 40% Total Enzyme Therapies Revenue $488 $449 9% $1,928 $1,718 12% KUVAN $28 $37